SCHEMBL18089331

SCHEMBL18089331

CN1CCN(C(=O)Oc2cc3c(c4ccccc24)C(CCl)CN3C(=O)OC(C)(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1A P07327 1/20 0.43
KIT P10721 1/20 0.43
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
ABL2 P42684 1/20 0.43
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
TLR9 Q9NR96 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
DTYMK P23919 2/20 0.36
CNR2 P34972 1/20 0.36
TP53 P04637 2/20 0.35
THRB P10828 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10066358 1.00 ADH1A (0.43) ADH1AKITFLT1FLT4KDR
SCHEMBL16486910 1.00 ADH1A (0.43) ADH1AKITFLT1FLT4KDR
SCHEMBL13007043 0.92 CHRM2 (0.40) CHRM2CHRM4CHRM1CHRM3TLR9
SCHEMBL20297102 0.89 ADH1A (0.46) ADH1AKITFLT1FLT4KDR
SCHEMBL21961762 0.87 ADH1A (0.41) ADH1AKITFLT1KDRABL2
SCHEMBL16933036 0.87 ADH1A (0.47) ADH1AKITFLT1FLT4KDR
SCHEMBL13007044 0.87 ADH1A (0.47) ADH1AKITFLT1FLT4KDR
SCHEMBL31036684 0.85 ADH1A (0.39) ADH1AKITFLT1FLT4KDR
SCHEMBL12596982 0.85 ADH1A (0.49) ADH1AKITFLT1FLT4KDR
SCHEMBL12596985 0.85 ADH1A (0.49) ADH1AKITFLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200289659-A1 CONJUGATES FOR TREATING DISEASES ENDOCYTE INC (US) 2020-09-17 US disclosed
WO-2016148674-A1 CONJUGATES FOR TREATING DISEASES ENDOCYTE, INC. (US) 2016-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289659-A1 CONJUGATES FOR TREATING DISEASES CD79B, MALT1, TPMT ADH1A 445/4885KIT 2248/4885FLT1 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.